Through the DCIDE program, the developer of a promising diagnostic agent or probe will be given access to the pre-clinical development resources of the National Cancer Institute in a manner that is intended to remove the most common barriers between laboratory discoveries and IND status.
Through a competitive selection process, the DCIDE program may supply assistance in any or all of the following activities:
The DCIDE program process will consist of two stages of evaluation. Stage 1 will be a competitive evaluation performed by a specially constituted DCIDE Evaluation Panel, consisting of non-NCI experts from academia and industry. This evaluation panel will provide individual opinions on the requests for resources. This evaluation panel will include imagers with molecular imaging expertise, molecular biologists, combinatorial chemists, radiochemists, pharmacists, and oncologists. Criteria for the initial evaluation are stated below. Requests for resources with sufficiently high merit scores will then move to Stage II, where a committee of NCI staff members will evaluate the scored requests for resources. NCI staff will select the requests for resources that are most consistent with resources available for expedited development.
Agents that undergo successful development and testing will be maintained in a probe library. The DCIDE library will be a source of probes that researchers may find beneficial in basic research, including in vivo animal model imaging studies. This resource may expand the clinical applications of the probes by providing better understanding of mechanisms and imaging criteria. Requests for probes for this purpose will undergo internal review at NCI to ensure study design appropriate to the proposed objectives. The DCIDE program will either provide agents directly or facilitate their availability. Radiotracer-labeled probes represent a special case that will require direct source / investigator affiliation, with NCI fulfilling mainly an informational role.